Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
Open accessThe DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid cells that have potent immune-suppressive activity. Studies in both mice and humans have demonstrated that MDSC accumulate in most individuals with cancer, where they promote tumor progression, inhibit antitumor immunity, and are an obstacle to many cancer immunotherapies. As a result, there has been intense interest in understanding the mechanisms and in situ conditions that regulate and sustain MDSC, and the mechanisms MDSC use to promote tumor progression. This article reviews the characterization of MDSC and how they are distinguished from neutrophils, describes the suppressive mechanisms used by MDSC to mediate their effects, and explains the role of proinflammatory mediators and the tumor microenvironment in driving MDSC accumulation, suppressive potency, and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 13×
“In contrast to STAT3, which promotes MDSC accumulation, IRF8 deters PMN-MDSC accumulation.”
BackgroundInfluentialCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · cited 1×
“Because there has been considerable discussion about the nomenclature, phenotype, and function of this cell population, an international group of investigators in the field recently recommended nomenclature and characterization standards for MDSC (15).”
BackgroundSelf-citationThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736 · cited 1×
“driving force for MDSC, and the hypothesis that one of the mechanisms by which inflammation drives cancer risk and tumor progression is through the suppression of antitumor immunity (47).”
Self-citationHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Research works printed but not linked: 1
- Geis-Asteggiante L 2017 Quantitative analysis of intact proteins and RNAs carried by immunosuppressive exosomes Ph.D. thesis University of Maryland
Cited by
Items 101–200 of 523
Li, Y., Xiang, S., Pan, W., Wang, J., Zhan, H., & Liu, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166860 · Cited by 72
Function of reactive oxygen species in myeloid-derived suppressor cells
Huang, J., Zhao, Y., Zhao, K., Yin, K., & Wang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226443 · Cited by 70
Cancer-associated inflammation: pathophysiology and clinical significance
Pęczek, P., Gajda, M., Rutkowski, K., Fudalej, M. M., Deptała, A., & Badowska-Kozakiewicz, A. M. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04399-y · Cited by 64
“It is noteworthy that MDSCs reduce effectiveness of numerous therapeutic strategies, such as immune checkpoint inhibition therapy, and hence, a number of current studies are focusing on eliminating them from the TME (Ostrand-Rosenberg and Fenselau 2018).”
BackgroundThe dual role of neutrophils in cancer
Shaul, M. E., & Fridlender, Z. G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101582 · Cited by 67
Tumino, N., Besi, F., Martini, S., Pace, A. L. D., Munari, E., Quatrini, L., Pelosi, A., Fiore, P. F., Fiscon, G., Paci, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803014 · Cited by 63
“Since exosomes were recently reported as an additional immunomodulatory mechanism, we assessed the possible contribution of PMN-MDSC-derived exosomes (51).”
BackgroundFleet, J. C., Burcham, G. N., Calvert, R. D., Elzey, B. D., & Ratliff, T. L. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105557 · Cited by 61
Supplementation of l ‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
Satoh, Y., Kotani, H., Iida, Y., Taniura, T., Notsu, Y., & Harada, M. (2020) · Cancer Science · doi:10.1111/cas.14490 · Cited by 62
Fleck, A.-K., Hucke, S., Teipel, F., Eschborn, M., Janoschka, C., Liebmann, M., Wami, H. T., Korn, L., Pickert, G., Hartwig, M., et al. (2021) · Brain · doi:10.1093/brain/awab040 · Cited by 60
Burgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 60
“TAMs 55,139 .”
Yang, B., Li, X., Fu, Y., Guo, E., Ye, Y., Li, F., Liu, S., Xiao, R., Liu, C., Lu, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2370 · Cited by 55
“KRAS-mutant cancers are characterized by abundant myeloid cell infiltration (46) with the extensive immunosuppressive myeloid cell environment, including MDSCs being postulated as a key cause of immunotherapy resistance (47).”
BackgroundCrosstalk Between Staphylococcus aureus and Innate Immunity: Focus on Immunometabolism
Horn, C. M., & Kielian, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621750 · Cited by 47
So, J. Y., Skrypek, N., Yang, H. H., Merchant, A. S., Nelson, G. W., Chen, W.-D. D., Ishii, H., Chen, J. M., Hu, G., Achyut, B. R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3339 · Cited by 57
LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs
Su, M., Kumata, S., Endo, S., Okada, Y., & Takai, T. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2060907 · Cited by 56
“exert immunosuppressive and tumor-promoting effects in the tumor environment.(6,37,38) Therefore, we examined whether these anti-tumor miRNAs were indeed increased in splenic gp49B MDSCs from tumor-bearing mice.”
BackgroundRNA Sequencing of the Tumor Microenvironment in Precision Cancer Immunotherapy
Lau, D., Bobe, A. M., & Khan, A. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.006 · Cited by 55
Joseph, E. L. M., Laheurte, C., Jary, M., Boullerot, L., Asgarov, K., Gravelin, E., Bouard, A., Rangan, L., Dosset, M., Borg, C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0326 · Cited by 55
Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy
Rapoport, B. L., Steel, H. C., Theron, A. J., Smit, T., & Anderson, R. (2020) · Molecules · doi:10.3390/molecules25071618 · Cited by 55
Tumor-Associated Neutrophils Drive B-cell Recruitment and Their Differentiation to Plasma Cells
Shaul, M. E., Zlotnik, A., Tidhar, E., Schwartz, A., Arpinati, L., Kaisar-Iluz, N., Mahroum, S., Mishalian, I., & Fridlender, Z. G. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0839 · Cited by 53
“A major mechanism through which neutrophils have been suggested to affect tumor growth has been via modulation of other infiltrating immune cells (10, 11).”
BackgroundNanomedicine for T‐Cell Mediated Immunotherapy
Li, F., Ouyang, J., Chen, Z., Zhou, Z., Essola, J. M., Ali, B., Wu, X., Zhu, M., Guo, W., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202301770 · Cited by 55
Lin, E., Liu, X., Liu, Y., Zhang, Z., Xie, L., Tian, K., Liu, J., & Yu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653358 · Cited by 59
Daneshmandi, S., Choi, J. E., Qi, Y., MacDonald, C. R., Pandey, M. R., Goruganthu, M., Roberts, N. T., Singh, P. K., Higashi, R. M., Lane, A. N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47096-9 · Cited by 53
Balog, J. Á., Hackler, L., Kovács, A., Neuperger, P., Alföldi, R., Nagy, L. I., Puskás, L. G., & Szebeni, G. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010170 · Cited by 56
“It has been widely known that the alternative polarization of the immune system, the accumulation of immature myeloid cells (MDSCs) with potent immunosuppression contribute to the cancer development [12,47].”
BackgroundNeutrophils as Suppressors of T Cell Proliferation: Does Age Matter?
Aarts, C. E. M., Hiemstra, I. H., Tool, A. T. J., van den Berg, T. K., Mul, E. P. J., van Bruggen, R., & Kuijpers, T. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02144 · Cited by 50
Rajabinejad, M., Salari, F., Karaji, A. G., & Rezaiemanesh, A. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1687504 · Cited by 51
“NF erythroid 2–related factor 2 (Nrf2) is a transcription factor that is responsible for this tolerance [29].”
BackgroundMarket, M., Tennakoon, G., & Auer, R. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111378 · Cited by 51
“However, while widely used, the efficacy of anti-Gr1 depletion on both MDSC subtypes is controversial, as M-MDSCs express less Gr1 [296,297].”
BackgroundTargeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting
Qiang, M., Chen, Z., Liu, H., Dong, J., Gong, K., Zhang, X., Huo, P., Zhu, J., Shao, Y., Ma, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516583 · Cited by 66
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 49
“This myeloid population conferees tumor tolerance and is generally expanded in cancer and inflammatory states [176].”
BackgroundKeenan, B. P., McCarthy, E. E., Ilano, A., Yang, H., Zhang, L., Allaire, K. M., Fan, Z., Li, T. Y., Lee, D. S., Sun, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111384 · Cited by 49
Acute myeloid leukaemia and the immune system: implications for immunotherapy
Barrett, A. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16310 · Cited by 52
Driving Immune Responses in the Ovarian Tumor Microenvironment
Ning, F., Cole, C. B., & Annunziata, C. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.604084 · Cited by 51
“Alternatively, cell types such as TAMs and MDSCs induce a highly immuno-suppressive TME and may be targets of future therapeutic strategies (6, 7).”
BackgroundBiochemistry, pharmacology, and in vivo function of arginases
Heuser, S. K., Li, J., Pudewell, S., LoBue, A., Li, Z., & Cortese-Krott, M. M. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001271 · Cited by 53
“…are a heterogeneous population of immature myeloid cells at different stages of myelopoiesis exerting immunosuppressive function through their ability to metabolize and deplete L -arginine, which is needed for T cell-mediated responses (Bronte et al, 2016; Ostrand-Rosenberg and Fenselau, 2018).”
Molecular Mechanisms in the Carcinogenesis of Oral Squamous Cell Carcinoma: A Literature Review
Cabral, L. G. D. S., Martins, I. M., Paulo, E. P. D. A., Pomini, K. T., Poyet, J., & Maria, D. A. (2025) · Biomolecules · doi:10.3390/biom15050621 · Cited by 57
S100A9 maintains myeloid-derived suppressor cells in chronic sepsis by inducing miR-21 and miR-181b
Alkhateeb, T., Kumbhare, A., Bah, I., Youssef, D. A., Yao, Z. Q., McCall, C. E., & Gazzar, M. E. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.04.019 · Cited by 47
Kuwahara‐Ota, S., Shimura, Y., Steinebach, C., Isa, R., Yamaguchi, J., Nishiyama, D., Fujibayashi, Y., Takimoto‐Shimomura, T., Mizuno, Y., Matsumura‐Kimoto, Y., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16881 · Cited by 45
“Development of a pharmacological strategy that targets MDSCs is an appealing research area in immuno-oncology,(25) and several drugs approved for cancer or non-cancerous diseases have inhibitory effects on MDSCs.(3,16,18,19) Indeed, our present study recapitulated a previous finding of the in vitro anti-MDSC effect of…”
BackgroundInfluentialPark, M. S., Yang, A., Lee, J. E., Kim, S., Roe, J., Park, M., Oh, M. J., An, H. J., & Kim, M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.015 · Cited by 49
Zeng, W., Liu, H., Mao, Y., Jiang, S., Hao, Y., Zhang, Z., Wang, M., & Zong, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5673 · Cited by 49
“Hypoxia‑inducible factor 1 α (HIF‑1 α ) stimulates the produc‑ tion of ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2), and ENTPD2 functions as an exonuclease on MDSCs, significantly contributing to their expansion within the CRC TME (17).”
BackgroundInfluentialKhan, A. N. H., Emmons, T. R., Wong, J. T., Alqassim, E., Singel, K. L., Mark, J., Smith, B. E., Tario, J. D., Eng, K. H., Moysich, K. B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0556 · Cited by 46
“Myeloid-derived suppressor cells (MDSC) are an immature, heterogeneous group ofmyeloid cells that suppress T-cell responses (1, 2).”
BackgroundMyeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression
Yin, K., Xia, X., Rui, K., Wang, T., & Wang, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.610104 · Cited by 47
“In addition, hypoxia can upregulate VEGF and functional molecule expression and lead to MDSCs accumulation in both mice and patients with lung cancer (58, 59).”
BackgroundLuker, A. J., Graham, L., Smith, T. M., Camarena, C., Zellner, M. P., Gilmer, J.-J. S., Damle, S., Conrad, D. H., Bear, H. D., & Martin, R. (2020) · BMC Immunology · doi:10.1186/s12865-020-0337-5 · Cited by 53
Kwong, T. T., Xiong, Z., Zhang, Y., Wu, H., Cao, J., Wong, P. P.-C., Liu, X., Wang, J., Wong, C. H., Tse, G. M.-K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.002 · Cited by 48
“47 However, the two still have certain distinctions in terms of biological roles and mediators, which may explain why discrete immunomodulation of the same combination therapy was obtained.”
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus
Dorhoi, A., Kotzé, L. A., Berzofsky, J. A., Sui, Y., Gabrilovich, D. I., Garg, A., Hafner, R., Khader, S. A., Schaible, U. E., Kaufmann, S. H. E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136288 · Cited by 47
Self-citationNew directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry
Maryamchik, E., Gallagher, K., Preffer, F. I., Kadauke, S., & Maus, M. V. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21880 · Cited by 45
“…popu- lation of cells that accumulate within the tumor, reduce its infiltration by the cytotoxic T cells, facilitate immune escape, and enable disease progression (Boissonnas et al., 2013; Lesokhin et al., 2012; Ochoa, Zea, Hernandez, & Rodriguez, 2007; Ostrand-Rosenberg & Fenselau, 2018).”
BackgroundLeveling Up the Controversial Role of Neutrophils in Cancer: When the Complexity Becomes Entangled
Sionov, R. V. (2021) · Cells · doi:10.3390/cells10092486 · Cited by 48
“Several terminologies have entered the literature describing the opposite features of neutrophils in cancer, such as “N1” and “N2” polarization [144], granulocyte myeloidderived suppressor cells (G-MDSCs) [47,145], neutrophil heterogeneity [65], neutrophil diversity [66], neutrophil plasticity [1,46,146], tumor-associ…”
BackgroundFarlow, J. L., Brenner, J. C., Lei, Y. L., & Chinn, S. B. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105420 · Cited by 42
“Furthermore, MDSCs encourage an antitumor environment through production of neoangiogenesis factors, MMPs, reactive oxygen species that prevent lymphocyte activation, sequestration of metabolites needed by effector cells, chemokine secretion, and cell-to-cell inhibitory contact with immune infiltrating cells [58].”
BackgroundSong, J., Eum, D., Park, S.-Y., Jin, Y., Shim, J.-W., Park, S.-J., Kim, M., Park, S.-J., Heo, K., & Choi, Y.-J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240533 · Cited by 44
“In addition, MDSCs secrete immunosuppressive cytokines that contribute to the induction of regulatory T cells, such as TGF-β and IL-10 [6].”
Sultan, M. A., Alghetaa, H., Mohammed, A. K., Abdulla, O. A., Wisniewski, P. J., Singh, N. P., Nagarkatti, P. S., & Nagarkatti, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.644281 · Cited by 41
“Tumorinduced MDSC inhibit T cell proliferation by causing L-arginine depletion through arginase-1 activity (Ostrand-Rosenberg and Fenselau, 2018), and in the current study, we did find that AEA induced increased expression of arginase-1.”
BackgroundMyeloid-Derived Suppressor Cells as a Potential Biomarker and Therapeutic Target in COVID-19
Rowlands, M., Segal, F., & Hartl, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697405 · Cited by 44
“In addition to these major suppressive mechanisms, other immuno-modulatory MDSC functions have been reported, including secretion of anti-inflammatory mediators such as interleukin-10 (IL-10), transforming growth factor beta (TGF-b) or Prostaglandin E2 (PGE2) or the Frontiers in Immunology | www.frontiersin.org 2 tryp…”
BackgroundResultInfluentialZare, E., Yaghoubi, S. M., Khoshnazar, M., Dargahlou, S. J., Machhar, J. S., Zheng, Z., Duijf, P. H. G., & Mansoori, B. (2025) · Cancers · doi:10.3390/cancers17132172 · Cited by 42
“They inhibit both innate and adaptive immune responses by preventing T cell activation and promoting the expansion of other immunosuppressive cell populations [175–177].”
Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectives
Safari, E., Ghorghanlu, S., Ahmadi‐khiavi, H., Mehranfar, S., Rezaei, R., & Motallebnezhad, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27923 · Cited by 41
Fultang, N., Li, X., Li, T., & Chen, Y. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.619253 · Cited by 43
“MDSCs are a significant obstacle to immunotherapies including checkpoint inhibitors; accumulation of MDSCs populations within circulating and tumor-infiltrating leukocytes have been observed in patients who fail to respond to checkpoint inhibitor therapy (18, 19).”
BackgroundTurning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
Rytlewski, J. D., Milhem, M. M., & Monga, V. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6041 · Cited by 42
“MDSCs include several immature non-macrophage cells sharing the ability to suppress T-cell function and T-cell activation (18).”
BackgroundRecent advances in the development of AHR antagonists in immuno-oncology
Sun, L. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00015b · Cited by 42
Shi, H., Li, K., Ni, Y., Liang, X., & Zhao, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707198 · Cited by 40
Revuri, V., Rajendrakumar, S. K., Park, M., Mohapatra, A., Uthaman, S., Mondal, J., Bae, W. K., Park, I., & Lee, Y. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100907 · Cited by 40
Khoury, M., Cohen, I., & Bar‐Sela, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020389 · Cited by 41
Edwards, C. M., & Johnson, R. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644303 · Cited by 39
“that PTHrP may play a critical role in negatively regulating tumor mass dormancy by increasing infiltration of immune suppressive MDSCs, which promote tumorigenesis (140, 141).”
BackgroundFletcher, R., Nunes, N. S., Patterson, M. T., Vinod, N., Khan, S. M., Mendu, S. K., Li, X., Pohl, A. D. P., Wachsmuth, L. P., Choo‐Wosoba, H., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022007026 · Cited by 39
Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes
Duetz, C., Westers, T. M., & van de Loosdrecht, A. A. (2018) · Pathobiology · doi:10.1159/000490727 · Cited by 40
Huang, H., Chang, C., Wang, C., & Lin, K. (2021) · Cells · doi:10.3390/cells10010067 · Cited by 43
“Furthermore, tumorsecreted factors promote the generation of myeloid-derived suppressor cells (MDSC) for recruitment to tumor surroundings, which inhibit T cell activity [8].”
BackgroundSei, S., Ahadova, A., Keskin, D. B., Bohaumilitzky, L., Gebert, J. F., Doeberitz, M. V. K., Lipkin, S. M., & Kloor, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1147590 · Cited by 38
Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies
Bhardwaj, V., & Ansell, S. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1129343 · Cited by 38
Physical activity delays accumulation of immunosuppressive myeloid-derived suppressor cells
Garritson, J. D., Krynski, L. M., Simon, L. H., Haughian, J. M., Pullen, N., & Hayward, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234548 · Cited by 41
“PMN-MDSCs were defined as CD11bLy6GLy6C and M-MDSCs were defined as CD11bLy6GLy6C [3].”
BackgroundInfluentialTumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Hao, S., Xu, S., Li, L., Li, Y., Zhao, M., Chen, J., Zhu, S., Xie, Y., Jiang, H., Zhu, J., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10165-7 · Cited by 38
Importance of myeloid derived suppressor cells in cancer from a biomarker perspective
Kalathil, S. G., & Thanavala, Y. M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104280 · Cited by 36
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 37
Role of Neutrophils on the Ocular Surface
Mun, Y., Hwang, J. S., & Shin, Y. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910386 · Cited by 37
“In additio , neutrophils can act as the myeloid-deriv d suppressor cells (MDSCs) to inhibit adaptive T cell functions such as the expansion of T cells, the activation f other immune cells, or the secretion of cytokines [11].”
BackgroundGibellini, L., Borella, R., Santacroce, E., Serattini, E., Boraldi, F., Quaglino, D., Aramini, B., Biasi, S. D., & Cossarizza, A. (2023) · Cancers · doi:10.3390/cancers15133327 · Cited by 37
The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer
García‐Estévez, L., González-Martínez, S., & Moreno‐Bueno, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.784823 · Cited by 37
Chhichholiya, Y., Ruthuparna, M., Velagaleti, H., & Munshi, A. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03050-z · Cited by 36
“A potent inflammatory mediator known as prostaglandin E2 (PGE2) is produced when arachidonic acid is converted by COX2 [91].”
BackgroundInfluentialSalminen, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102694 · Cited by 34
Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges
Chen, R., Johnson, J. E., Roudkoli, A. R., & Dudek, A. Z. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2024-000566 · Cited by 36
Molecular cargo in myeloid-derived suppressor cells and their exosomes
Fenselau, C., & Ostrand‐Rosenberg, S. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104258 · Cited by 34
“These cells are of great interest in cancer because they suppress the adaptive immune response mediated by CD4+ and CD8+ T cells, promote solid tumor neovascularization, and facilitate cancer stem cell development [1, 2].”
BackgroundSelf-citationTreating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
Ho, M., Xiao, A. H., Yi, D., Zanwar, S., & Bianchi, G. (2022) · Current Oncology · doi:10.3390/curroncol29110705 · Cited by 34
Horner, E., Lord, J. M., & Hazeldine, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1239683 · Cited by 35
Application of Anti-Inflammatory Agents in Prostate Cancer
Hatano, K., Fujita, K., & Nonomura, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082680 · Cited by 33
Groth, C., Arpinati, L., Shaul, M. E., Winkler, N., Diester, K., Gengenbacher, N., Weber, R., Arkhypov, I., Lasser, S., Petrova, V., et al. (2021) · Cancers · doi:10.3390/cancers13040726 · Cited by 34
“Although it was previously demonstrated that M-MDSC produced more NO, whereas PMN-MDSC showed higher ROS production [41], we did not detect significant differences in the production of these immunosuppressive factors by both MDSC subsets.”
ResultRole of myeloid-derived suppressor cells in tumor recurrence
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10079-1 · Cited by 33
“Recent studies have supported this observation with the finding that pulmonary fibrosis has a pathobiology similar to MDSCs in cancer [115] based on a common role for CXCR2 in tumor-associated increase in MDSCs [116].”
ResultYang, Z., Teng, Y., Lin, M. S., Peng, Y., Du, Y., Sun, Q., Gao, D., Yuan, Q., Zhou, Y. J., Yang, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c13143 · Cited by 33
Obesity as an immune-modifying factor in cancer immunotherapy
Canter, R. J., Le, C. T., Beerthuijzen, J. M. T., & Murphy, W. J. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri1017-401rr · Cited by 34
Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics
Rai, A., Noor, S., Ahmad, S. I., Alajmi, M. F., Hussain, A., Abbas, H., & Hasan, G. M. (2021) · Medicina · doi:10.3390/medicina57020091 · Cited by 34
“There are two populations of tumor-bearing MDSC hosts: polymorphonuclear cells (PMN-MDSC) and monocytic cells (MMDSC), which can promote metastasis, tumor cell invasion, and angiogenesis due to their immune suppressive activity [110].”
BackgroundHot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 35
Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy
Deng, K., Yang, D., & Zhou, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071344 · Cited by 33
Hosoya, T., Sato-Kaneko, F., Ahmadi, A., Yao, S., Lao, F. S., Kitaura, K., Matsutani, T., Carson, D. A., & Hayashi, T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803281115 · Cited by 31
“Cancer in the lungs can create an immunosuppressive and angiogenic microenvironment (4, 5).”
BackgroundLi, J., Li, H., Yu, Y., Liu, Y., Liu, Y., Ma, Q., Zhang, L., Lu, X., Wang, X., Chen, Z., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1527650 · Cited by 32
MicroRNAs and lncRNAs—A New Layer of Myeloid-Derived Suppressor Cells Regulation
Safarzadeh, E., Asadzadeh, Z., Safaei, S., Hatefi, A., Derakhshani, A., Giovannelli, F., Brunetti, O., Silvestris, N., & Baradaran, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.572323 · Cited by 31
Sanchez‐Pino, M. D., Gilmore, L. A., Ochoa, A. C., & Brown, J. C. (2021) · Obesity · doi:10.1002/oby.23108 · Cited by 32
Jeong, H., Lee, S. Y., Seo, H., & Kim, B. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003180 · Cited by 33
Lu, Z., Ma, L., Mei, L., Ren, K., Li, M., Zhang, L., Liu, X., & He, Q. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122303 · Cited by 32
Immune regulation and anti-cancer activity by lipid inflammatory mediators
Khadge, S., Sharp, J. G., McGuire, T. R., Thiele, G. M., Black, P. N., Dirusso, C., Cook, L. M., Klassen, L. W., & Talmadge, J. E. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.026 · Cited by 35
Geng, F., Guo, J., Guo, Q., Xie, Y., Dong, L., Zhou, Y., Liu, C., Yu, B., Wu, H., Wu, J., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.06.012 · Cited by 32
Xu, Y., Miller, C. P., Tykodi, S. S., Akilesh, S., & Warren, E. H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1387198 · Cited by 31
Natural biomolecules and derivatives as anticancer immunomodulatory agents
Bernitsa, S., Dayan, R., Stephanou, A., Tzvetanova, I. D., & Patrikios, I. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070367 · Cited by 35
Inflammatory processes involved in NASH-related hepatocellular carcinoma
Cannito, S., Dianzani, U., Parola, M., Albano, E., & Sutti, S. (2023) · Bioscience Reports · doi:10.1042/bsr20221271 · Cited by 31
Innate Immune Defense Mechanisms by Myeloid Cells That Hamper Cancer Immunotherapy
Lebegge, E., Arnouk, S. M., Bardet, P. M. R., Kiss, M., Raes, G., & Ginderachter, J. A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01395 · Cited by 30
Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies
Parizi, M. S., Salemizadehparizi, F., Abdolhosseini, S., Vanaei, S., Manzouri, A., & Ebrahimzadeh, F. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00878-9 · Cited by 31
Gross, D., Chintala, N. K., Vaghjiani, R. G., Grosser, R. A., Tan, K. S., Li, X., Choe, J. K., Li, Y., Aly, R. G. M., Emoto, K., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.09.009 · Cited by 34
Lee, J. M., Tsuboi, M., Kim, E. S., Mok, T. S. K., & Garrido, P. (2022) · Future Oncology · doi:10.2217/fon-2021-1567 · Cited by 30
Dai, J., Wu, M., Xu, Y., Yao, H., Lou, X., Hong, Y., Zhou, J. Q., Xia, F., & Wang, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10417 · Cited by 29
“The immunosuppressive state of the tumor microenvironment is enforced via immune cell subsets recruited or induced, such as T cell, dendritic cells, and natural killer cells.(18) It is suggested”
BackgroundOstrand‐Rosenberg, S., Huecksteadt, T. P., & Sanders, K. A. (2023) · Cancers · doi:10.3390/cancers15041026 · Cited by 31
“MDSCs are potent immune suppressive cells that profoundly inhibit antitumor immunity and promote tumor progression through a variety of mechanisms that include blocking T cell and NK cell activation and function, inducing T regulatory cells, promoting pro-tumor macrophage activity, and facilitating angiogenesis and in…”
BackgroundSelf-citationDiverse functions of myeloid-derived suppressor cells in autoimmune diseases
Xiong, X., Zhang, Y., & Wen, Y. (2023) · Immunologic Research · doi:10.1007/s12026-023-09421-0 · Cited by 28
“Cytokines, immune regulatory molecules, and transcription factors can alter the recruitment, suppressive potency, and survival of MDSCs [112].”
Background
Metadata
- Authors
- Ostrand-Rosenberg, S., & Fenselau, C.
- Affiliations
- Department of Biological Sciences, University of Maryland Baltimore County , Baltimore, MD 21250
- University of Maryland, College Park (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 422-431
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5765878
- OpenAlex
- W2783633531
- Cited by
- 509
- References
- 135
- Citations by year
- 2026: 34 · 2025: 42 · 2024: 44 · 2023: 61 · 2022: 71 · 2021: 117 · 2020: 80 · 2019: 39 · 2018: 21
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion)
- Digital Repository at the University of Maryland (University of Maryland College Park)
- Funders
- National Institutes of Health (1s10od019938-01, RO1 GM021248)
- National Cancer Institute (R01CA084232, R01CA115880)
- National Institute of General Medical Sciences (R01GM021248)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor immunosuppression, antitumor immunity, tumor microenvironment, pro-inflammatory mediators, neutrophils, cancer immunotherapy resistance, tumor progression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Humans, Neoplasms, Phenotype, Cytokines, Disease Progression, Inflammation Mediators, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.